Verona

Verona's COPD drug hits goal in phase 3, teeing up FDA filing

Verona has hit the mark in its first of two phase 3 COPD trials, keeping it on course to file for FDA approval of the inhaled PDE3 and PDE4 inhibitor.

Nick Paul Taylor Aug 9, 2022 6:40am

Frontier launches with biotech vet CEO—Chutes & Ladders

Jun 28, 2019 9:30am

Verona hires ex-GSK researchers for late-phase push in COPD

Jun 25, 2019 8:10am

Verona tanks after COPD drug misses phase 2 endpoint

Jan 14, 2019 9:25am

Verona jumps as midphase cystic fibrosis data dial up hopes

Mar 2, 2018 9:25am

Theravance COPD drug on track for FDA decision by November

Jan 29, 2018 11:15am